Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTP1B siRNA
- Development stage
- Preclinical
- Lead developer
- CIB
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Subcutaneous
01
Overview
PTP1B siRNA is a small interfering RNA designed to silence the expression of **Protein-tyrosine phosphatase 1B (PTP1B)**, a non-receptor tyrosine phosphatase encoded by the *PTPN1* gene. In the context of glioblastoma (GBM) research, PTP1B has been identified as a critical mediator of the IL-13/IL13Rα2 signaling axis, which promotes tumor aggressiveness, migration, and invasion. By silencing PTP1B, this siRNA inhibits the IL-13-mediated activation of downstream oncogenic pathways, including **Src (Tyr419)**, **AKT**, and **ERK1/2**. Research conducted by the Centro de Investigaciones Biológicas and Northwestern University suggests that targeting PTP1B can revert the pro-metastatic capacities of GBM cells, making it a viable therapeutic target for preventing tumor progression and invasion.
- Other names
- Protein-tyrosine phosphatase 1B siRNAPTPN1 siRNAPTPN-1 siRNAPTPN 1 siRNAsiRNA targeting PTP1B
02
Targets
PTPN1 (Protein tyrosine phosphatase 1B)
Beyond the preview
Go deeper on PTP1B siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTP1B siRNA.